

Supplementary Scheme 1: Metabolic oligosaccharide engineering.



Ac₄GalNAz (100 µM) Na-L-ascorbat (50 µg/ml)


6 days, cell culture conditions

primary human fibroblasts



fibroblasts with azide-modified glycans

Supplementary Scheme 2: Isolation of azide-modified *click*ECM.



fibroblasts with azide-modified glycans

- 1. wash cell culture with H_2O
- 2. lyse cells with NH_4OH (20 mM)
- (3-5 min, 37 °C)3. rinse ECM with H₂O





azide-modified, fibroblast cell-derived ECM (*click*ECM)

Supplementary Scheme 3: Detection of azide groups in formalin-fixed samples via coppercatalyzed azide-alkyne cycloaddition with an alkyne-modified fluorophore.

A Fibroblast cell cultures


B clickECM







Alexa Fluor® 488 Alkyne

Click-iT[®] Cell Reaction Buffer Kit 30 min, room temperature







Alexa Fluor[®] 488 Alkyne

Click-iT[®] Cell Reaction Buffer Kit 30 min, room temperature




Supplementary Scheme 4: Alkyne modification of artificial surfaces (silicon wafers).

A Surface activation with ammonium hydroxide and hydrogen peroxide

OH OH H₂O₂/NH₄OH (2:3) 70 °C, 40 min **B** Silanization ΟН ОН Carboxyethylsilanetriol соон соон room temperature, 1 min **C** Functionalization with alkyne groups (DIBO-functionalized surfaces) DIBO-OEG-NH₂ (125 µM) соон соон EDC (5 mg/ml) room temperature, over night **D** Functionalization with Ac-OEG-linker (control) Ac-OEG-NH₂ (125 µM) соон соон EDC (5 mg/ml) room temperature, over night

Supplementary Scheme 5: Detection of the immobilized DIBO group with an azide-modified fluorophore (copper-free azide-alkyne cycloaddition).

A DIBO-functionalized surfaces




B Control: unspecific interaction of an immobilized Ac-OEG-linker with the azide-modified fluorophore.




Supplementary Scheme 6:

A Covalent immobilization of azide-modified *click*ECM on DIBO-functionalized artificial surfaces (silicon-wafers).




B Preparation of control substrates via physisorption of unmodified ECM on DIBOfunctionalized artificial surfaces (silicon-wafers).





unmodified ECM




min. 2 h at room temperature

Chemical Syntheses

General Methods. NEt₃ was distilled from CaH₂ before usage. Analytical thin layer chromatography (TLC) was carried out on silica gel 60 F₂₅₄ coated aluminum sheets from *Merck* with detection under UV light ($\lambda = 254$ nm). Additionally, the TLC plates were charred using ethanolic ninhydrin solution (3 % w/v) or *p*-anisaldehyde (3.7 mL *p*-anisaldehyde, 5 mL conc. H₂SO₄ and 1.4 mL HOAc in 135 mL dry EtOH) staining solution. Flash column chromatography (FC) was performed on silica 60 (40-63 µm) from *Merck*. NMR spectra were recorded on Bruker Avance III 400 instruments. Chemical shifts are given in ppm and referenced to the solvent signal (CDCl₃: $\delta_H = 7.26 \ \delta_C = 77.16$, CD₃OD: $\delta_H = 3.31$, $\delta_C = 49.0$). Assignment of proton and carbon resonances was achieved by two-dimensional COSY, HSQC, and HMBC experiments. LC-ESI-MS analyses were conducted on a LCMS2020 instrument from *Shimadzu* (pumps LC-20 AD, autosampler SIL-20AT HAT, column oven CTO-20AC, UV-Vis detector SPD-20A, controller CBM-20, ESI detector and software LCMS-solution) with an EC 125/4 Nucleodur C18, 3 µM column (*Machery-Nagel*). HRMS analyses were performed on a *micrOTOF II* instrument from *Bruker* in positive mode.


 $Ac_4GalNAz^1$ and $Ac_4GalNAc^2$ were synthesized according to published procedures. From both monosaccharides stock solutions (100 mM) in DMSO were prepared. Prior to cell treatment, these stock solutions were diluted to 10 mM in PBS and sterile filtered.

Synthesis of DIBO-OEG-NH₂




Supplementary Scheme 7: Synthesis of DIBO-OEG-NH₂

7,8-Didehydro-1,2:5,6-dibenzocyclooctene-3-yl (3-(2-(3-*N*-Boc-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (3)




Carbonate 1³ (46 mg, 119 µmol) was dissolved in dry DMF. Tri(ethylene glycol) derivative **2** (107 mg, 334 µmol) and dry NEt₃ (50 µL, 360 µmol) were added and the solution was stirred at RT. When TLC showed complete consumption of **1**, the solvent was removed under reduced pressure and the residue coevaporated 3 times with toluene. FC (petroleum ether/EtOAc 1:1 to 1:3) afforded **3** (68 mg, quant.) as pale oil. TLC (petroleum ether/EtOAc, 1:3): $R_{\rm f} = 0.33$; ¹H NMR (400.1 MHz, CD₃OD): $\delta = 7.56$ (d, J = 7.8 Hz, 1H, Ar-H), 7.44-7.25 (m, 7H, Ar-H), 5.43 (m, 1H, H-8), 3.70-3.51 (m, 10H, OCH₂CH₂ 3^{'''},4^{'''},5^{'''},6^{'''},7^{'''}), 3.49 (t, 2H, CH₂ 8^{'''}), 3.25-3.17 (m, 3H, H-7a and CH₂ 1^{'''}), 3.10 (t, J = 6.8 Hz, 2H, CH₂ 10^{'''}), 2.83 (dd, J = 14.9, 3.8 Hz, 1H, H-7b) 1.77 (quint, J = 6.4 Hz, 2H, CH₂ 2^{'''}), 1.70 (quint, J = 6.5 Hz, 2H, CH₂ 9^{'''}), 1.42 (s, 9H, 3 x CH₃); ¹³C NMR (100.6 MHz, CD₃OD): $\delta = 158.4$ (C=O), 157.9 (C=O), 153.7 (quart.), 152.4 (quart.), 131.0 (C-1'), 129.3, 129.2, 128.3 (C-3''), 128.2, 127.2, 126.9, 125.0 (C-1'), 124.9, 122.4 (C-2), 113.8 (C-4), 111.0 (C-3), 79.9 (C(CH₃)₃), 77.8 (C-8), 2 x 71.5, 71.3, 71.2 (C-4^{'''}-C-7^{''''}), 69.9, 69.8 (C-3^{'''} and C-8^{'''}), 47.2 (C-7), 39.2 (C-1^{'''}), 38.7 (C-10^{'''}), 2 x 30.9 (C-2^{'''} and C-9^{'''}), 3 x 28.8 (CH₃); HRMS: *m/z* calcd for C₃₂H₄₃N₂O₇: 567.3065 [M+H]⁺, found: 567.3040.

DIBO-OEG-NH₂




Compound **3** (66 mg, 116 µmol) was dissolved in 2 M HCl in EtOAc (2.5 mL) and the solution was stirred at RT. After complete consumption of starting material, the reaction mixture was diluted with toluene (4 mL) and then the solvent was removed under reduced pressure. DIBO-OEG-NH₂ (52 mg, 89 %) was obtained as pale yellow oil. TLC (CH₂Cl₂/MeOH 9:1) R_f = 0.22; ¹H NMR (399.8 MHz, CD₃OD): δ = 7.90 (s, 1H, C(O)NH), 7.57 (d, *J* = 7.7 Hz, 1H, Ar-H), 7.44-7.25 (m, 7H, Ar-H), 5.43 (m, 1H, H-8), 3.70-3.45 (m, 12H, OC<u>H</u>₂CH₂ 3^{*in*}, 4^{*in*}, 5^{*in*}, 6^{*in*}, 7^{*in*}, 8^{*in*}), 3.26-3.16 (m, 3H, H-7a and CH₂ 1^{*in*}), 2.89-2.76 (m, 3H, H-7b and CH₂ 10^{*in*}), 1.82-1.69 (m, 4H, CH₂ 2^{*in*} and CH₂ 9^{*in*}); ¹³C NMR (100.5 MHz, CD₃OD): δ = 158.0 (C=O), 153.6 (quart.), 152.4 (quart.), 131.0 (C-1'), 129.3, 129.2, 128.3 (C-3''), 128.2, 127.2, 126.9, 2 x 124.9, 122.4 (C-2), 113.8 (C-4), 111.0 (C-3), 77.8 (C-8), 71.4, 71.2, 71.1, 71.0 (C-4^{*in*}-C-7^{*in*}), 70.4, 69.5 (C-3^{*in*} and C-8^{*in*}), 47.2 (C-7), 40.1 (C-1^{*in*}), 39.1 (C-10^{*in*}), 30.9, 30.2 (C-2^{*in*} and C-9^{*in*}); HRMS: *m/z* calcd for C₂₇H₃₄N₂O₅: 467.2540 [M+H]⁺, found: 467.2527.

Synthesis of Ac-OEG-NH₂




Supplementary Scheme 8: Synthesis of Ac-OEG-NH₂

tert-Butyl(2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (4)



Tri(ethylene glycol) derivative **2** (270 mg, 843 µmol) was dissolved in pyridine (2 mL) and Ac₂O (172 mg, 1.69 mmol) was added. According to TLC the reaction was completed after 45 min. The solvent was removed under reduced pressure and the residue 3 times coevaporated with toluene. FC (CH₂Cl₂ to CH₂Cl₂/MeOH 19:1) afforded **4** (250 mg, 82 %) as pale oil. TLC (EtOAc/MeOH 9:1): $R_f = 0.6$; ¹H NMR (400.1 MHz, CDCl₃,): $\delta = 6.64$ (br s, 1H, NHAc), 5.08 (br s, 1H, NHBoc), 3.57-3.35 (m, 12 H, 6 x CH₂), 3.20 (q, J = 6.1 Hz, 2H, CH₂NHAc), 3.07 (q. J = 6.0 Hz, 2H, CH₂NHBoc), 1.82 (s, 3H, CH₃CO), 1.70-1.56 (m, 4H, 2 x CH₂), 1.29 (s, 9H, 3 x CH₃). ¹³C NMR (100.6 MHz, CDCl₃): 170.1 (C(O)CH₃), 155.9 (C(O)O), 78.6 (C quart., C-2), 2 x 70.3, 69.9, 69.8, 69.3 (5 x CH₂), 38.3, 37.7 (2 x CH₂NH), 29.5, 28.8 (2 x CH₂), 28.3 (3 x (CH₃)₃CO), 23.0 (CH₃CO); HRMS: *m/z* calcd for C₁₇H₃₅N₂O₆: 363.2457 [M+H]⁺, found: 363.2474.

Ac-OEG-NH₂




Compound **4** (249 mg, 687 µmol) was dissolved in dry DCM (1.6 mL) and cooled to 0 °C. TFA (800 µL) was added and the mixture stirred at RT. After 1 h TLC showed complete conversion of starting material. The solvent was removed under reduced pressure and the residue was coevaporated 3 times with toluene. The residue was dissolved in H₂O (2 mL) and lyophilized. This was repeated 2 times. Ac-OEG-NH₂ (241 mg, 93 %) was obtained as pale oil. TLC (CH₂Cl₂/MeOH 3:1): $R_{\rm f}$ = 0.05; ¹H NMR (400.1 MHz, CD₃OD): δ = 3.69-3.61 (m, 8H, 4 x CH₂), 3.61-3.57 (m, 2H, CH₂), 3.51 (t, *J* = 6.1 Hz, 2H, CH₂), 3.24 (t, *J* = 7.0 Hz, 2H,

CH₂), 3.09 (t, J = 6.4 Hz, 2H, CH₂), 1.96-1.88 (m, 5H, CH₃ and CH₂), 1.75 (m, 2 H, CH₂); ¹³C NMR (100.6 MHz, CD₃OD): $\delta = 173.3$ (C=O), 71.4, 71.1, 2 x 71.0 (C-4 – C7), 70.4, 69.6 (C-3 and C-8), 40.1 (C-1), 37.8 (C-10), 30.5 (C-2), 28.1 (C-9), 22.6 (CH₃); HRMS: *m*/*z* calcd for C₁₇H₂₇N₂O₄: 263.1965 [M+H]⁺, found: 263.1956.


From both DIBO-OEG-NH₂ and Ac-OEG-NH₂ stock solutions (125 mM) in DMSO were prepared.

References


- 1 Hang, H. C., Yu, C., Kato, D. L. & Bertozzi, C. R. A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 14846-14851, doi:10.1073/pnas.2335201100 (2003).
- Traar, P., Belaj, F. & Francesconi, K. A. Synthesis of methyl 2-acetamido-2-deoxy-1-selenobeta-D-gluco- and galacto-pyranoside: Selenium metabolites in human urine. *Aust. J. Chem.* 57, 1051-1053, doi:10.1071/ch04176 (2004).
- 3 Ning, X., Guo, J., Wolfert, Margreet A. & Boons, G.-J. Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions. *Angew. Chem., Int. Ed.* **47**, 2253-2255, doi:10.1002/anie.200705456 (2008).





¹H NMR spectrum (400.1 MHz, CD₃OD) of compound **3**



¹³C NMR spectrum (100.6 MHz, CD₃OD) of compound **3**







AcHN² NH₂∙TFA \cap Ac-OEG-NH₂ HDO 4.90 ↓ 2.02 ↓ 7.99 1.99 1.99 3.5 δ (ppm) 7.0 6.5 6.0 5.5 5.0 4.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 4.0 ¹H NMR spectrum (400.1 MHz, CD₃OD) of Ac-OEG-NH₂ 71.4 71.1 71.0 71.0 69.6 -40.1 -30.5 -28.1 -22.6 `NH₂⁺TFA AcHN C റ Ac-OEG-NH₂

110

100 90 δ (ppm) 80

70

60

50

40

30

20

10

120

140

150

130

:00

190

180

170

160

¹³C NMR spectrum (100.5 MHz, CD₃OD) of DIBO-OEG-NH₂

0

¹³C NMR spectrum (100.6 MHz, CD₃OD) of Ac-OEG-NH₂